Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
M3 FY26 Q1 profit attributable to owners drops 23.4% to JPY 9.07 billion; revenue rises 4.5% to JPY 90.11 billion

M3 FY26 Q1 profit attributable to owners drops 23.4% to JPY 9.07 billion; revenue rises 4.5% to JPY 90.11 billion

ReutersReuters2026/08/06 06:50
  • M3 posted Q1 IFRS revenue of JPY 90.11 billion, up 4.5% year on year; operating profit fell 8.6% to JPY 18.08 billion.
  • Profit attributable to owners of the parent slid 23.4% to JPY 9.07 billion; EPS dropped to JPY 13.6 from JPY 17.44.
  • Overseas segment revenue rose 9.8% to JPY 22.75 billion, while segment profit dipped 4.9% to JPY 4.62 billion on upfront investments.
  • Site Solution revenue climbed 9% to JPY 14.16 billion, but segment profit plunged to JPY 15 million due to upfront investments for new facility openings.
  • M3 kept its FY2027 forecast unchanged, projecting revenue of JPY 400 billion with operating profit of JPY 80 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. M3 Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage